Strategic Frameworks For Cell Line Development: A Methodology For Long-Term Program Viability

Reaching a research or master cell bank quickly is still the usual measure of cell line development progress, yet it says little about whether a clone will hold up through scale-up, tech transfer, and regulatory review. John Gill, Vice President and Scientific Leader of Cell Line Development at Abzena, argues that bispecifics, T-cell engagers, and Fc-fusion proteins expose the limits of rigid, templated platforms. He sets out a four-pillar framework built on manufacturability, analytical readiness, clone stability, and regulatory strategy, and describes how stable pools and upfront design choices can surface risk sooner. He also outlines what to look for in a CDMO partner. Read Gill's analysis to see how the pillars inform one another.